What Is Next Best Action (NBA) in Pharma? How AI, Real-World Data, and Omnichannel Engagement Are Reshaping Commercial Strategy

For decades, pharmaceutical commercialization followed a relatively predictable model.

Commercial teams segmented healthcare providers into prescribing tiers, aligned territories around geography, deployed field reps against high-volume physicians, and measured success primarily through prescription lift. The dominant assumption was simple: the more often a physician was engaged, the more likely prescribing behavior would change.

That model worked reasonably well in large primary care markets where:

• treatment pathways were straightforward,
• physicians had relatively open access,
• and most therapies competed within broad populations.

But modern healthcare no longer behaves like that.

Today’s pharmaceutical environment is shaped by:

• precision medicine,
• fragmented referral ecosystems,
• integrated delivery networks (IDNs),
• biomarker-driven treatment decisions,
• digital engagement fatigue,
• and physicians who increasingly expect highly personalized scientific interactions.

At the same time, healthcare providers are becoming dramatically harder to engage through traditional channels. Many health systems now heavily restrict in-person rep access, physicians are overwhelmed with content across email and digital channels, and therapeutic complexity has increased substantially — particularly in oncology, immunology, neurology, and rare disease.

This has fundamentally changed the nature of pharmaceutical commercialization.

The central challenge is no longer simply:

“Who writes the most prescriptions today?”

Instead, modern commercial organizations are trying to answer much more nuanced questions:

• Which physicians are beginning to diagnose the right patients?
• Which providers influence treatment decisions without directly prescribing?
• Which accounts are likely to adopt new therapies fastest?
• Which physicians respond better to scientific education than promotional outreach?
• Which HCPs are highly clinically active but commercially disengaged?
• Which providers are increasing biomarker testing activity?
• Which physicians should be engaged by medical affairs versus the field force?
• Which accounts represent hidden future opportunity before prescribing trends fully emerge?

This shift is what gave rise to one of the most important concepts in modern pharma commercialization:

Next Best Action (NBA).

What Does “Next Best Action” Actually Mean?

At its core, Next Best Action refers to using:

• healthcare data,
• behavioral analytics,
• AI models,
• and engagement signals

to determine the most effective next step a pharmaceutical organization should take with a healthcare provider, account, or health system.

Importantly, NBA is not simply about automation.

The goal is not merely:

“automatically tell reps who to visit.”

The real objective is to dynamically orchestrate commercial engagement based on continuously changing provider behavior, patient opportunity, and healthcare ecosystem dynamics.

In practice, a Next Best Action recommendation could involve:

• scheduling a field rep visit,
• routing an HCP toward medical affairs engagement,
• prioritizing scientific education,
• inviting a physician to a speaker program,
• reducing promotional frequency,
• escalating digital engagement,
• or identifying a provider as an emerging referral influencer.

A modern NBA engine may generate recommendations such as:

“Dr. Chen has shown increasing ICD-10 diagnosis activity associated with refractory atopic dermatitis, recently attended two sponsored educational events, and referred multiple patients into a tertiary specialty center. Recommend follow-up through immunology field engagement with biomarker-focused educational content within 7 days.”

What makes this fundamentally different from traditional pharma targeting is that the recommendation is:

• contextual,
• dynamic,
• behavioral,
• and continuously evolving.

Historically, many physicians were treated similarly simply because they fell into the same prescribing decile. Modern NBA systems attempt to understand:

• why a physician matters,
• how they influence treatment pathways,
• and what type of engagement is most likely to resonate.

Why Traditional Pharma Commercial Models Started Breaking Down

To understand why NBA became strategically important, it helps to understand how dramatically physician engagement has changed over the last fifteen years.

Historically, pharmaceutical sales models were largely optimized around physical access. The field force was the center of commercial strategy, and rep frequency often served as the primary operational KPI.

But several major industry shifts permanently altered that environment.

First, healthcare systems consolidated rapidly. Physicians increasingly became employees of:

• large health systems,
• integrated delivery networks,
• academic centers,
• and multispecialty organizations.

This reduced individual physician autonomy while increasing institutional complexity.

Second, physician access declined dramatically. Many organizations began restricting in-person pharmaceutical engagement entirely. In some therapeutic areas, physicians became almost impossible to reach through traditional field models.

Third, treatment complexity exploded.

Modern therapies increasingly involve:

• biomarkers,
• companion diagnostics,
• specialty referral pathways,
• multidisciplinary coordination,
• and highly specific patient populations.

In oncology, for example, a physician’s importance may have very little to do with current prescription volume alone. A provider may influence future market opportunity because they:

• identify biomarker-positive patients,
• control referral flow,
• or diagnose disease earlier than peers.

Traditional commercial segmentation systems struggled to capture this nuance.

At the same time, physicians themselves became far more selective about engagement. HCPs increasingly expect interactions that are:

• relevant,
• personalized,
• scientifically meaningful,
• and channel-appropriate.

As McKinsey observed in its research on personalization in pharma:

“Traditional segmentation approaches are no longer sufficient to meet rising HCP expectations for relevance and personalization.”

That sentence captures the core reason NBA has become so important. Commercial engagement can no longer rely on static targeting models alone.

The Evolution of NBA: From Call Plans to AI Orchestration

The development of NBA in pharma occurred gradually over multiple generations of commercial technology.

The earliest commercial systems were largely built around static physician segmentation. Organizations grouped physicians based on:

• prescription volume,
• specialty,
• geography,
• and market share.

Targeting plans were often updated quarterly or annually, and field reps executed standardized call plans across assigned territories.

This model worked reasonably well in broad primary care markets but became increasingly ineffective in specialty therapeutics where:

• referral influence mattered,
• patient pathways were fragmented,
• and treatment decisions involved multiple stakeholders.

The next evolution came with CRM systems and multichannel engagement platforms. As systems like Veeva Systems and Salesforce became embedded across commercial operations, organizations gained significantly more visibility into:

• rep activity,
• digital engagement,
• webinar attendance,
• and email responsiveness.

This enabled the first generation of rules-based recommendations.

For example:

• if a physician attended a webinar but did not respond afterward,
• the system might automatically trigger rep follow-up.

But these systems were still largely reactive and channel-specific. They lacked deeper understanding of:

• patient opportunity,
• referral influence,
• clinical complexity,
• and physician behavior.

Modern NBA systems evolved beyond rules engines by integrating:

• claims intelligence,
• ICD-10 diagnosis activity,
• biomarker behavior,
• provider affiliations,
• referral networks,
• Open Payments data,
• and omnichannel engagement signals.

This shift allowed organizations to move from:

“high prescriber targeting”

toward:

“dynamic provider intelligence.”

Real-World Examples of NBA in Practice

Consider an oncology launch.

Historically, a pharmaceutical company might prioritize physicians primarily based on:

• current prescribing volume,
• publication activity,
• or conference participation.

But modern oncology treatment pathways are deeply influenced by:

• biomarker testing,
• referral dynamics,
• molecular diagnostics,
• and multidisciplinary coordination.

An NBA system may detect that:

• a community oncologist recently increased biomarker testing,
• began diagnosing higher volumes of NSCLC-related ICD-10 codes,
• referred patients into a tertiary academic center,
• and attended multiple educational programs related to targeted therapies.

Even if prescribing behavior has not yet changed significantly, the system may recognize this physician as an emerging adoption opportunity.

The recommendation may not be:

“increase rep visits.”

Instead, the optimal engagement could involve:

• routing the physician toward scientific education,
• prioritizing medical affairs engagement,
• or providing biomarker testing support resources.

This is where modern healthcare commercial intelligence platforms like Alpha Sophia are increasingly valuable. By combining:

• healthcare claims,
• provider affiliations,
• ICD-10 diagnosis activity,
• and healthcare engagement data,

commercial organizations can identify patterns that traditional CRM systems often miss entirely.

Open Payments Data and the Rise of “Promo Resistance” Analysis

One particularly interesting evolution within NBA involves understanding commercial receptiveness itself.

Historically, pharmaceutical organizations often assumed all physicians within a segment should receive similar engagement intensity. But modern engagement behavior is much more nuanced.

Some physicians:

• actively participate in sponsored educational events,
• engage heavily with peer programs,
• and consistently interact with commercial content.

Others may:

• manage extremely large patient populations,
• diagnose significant disease volume,
• yet remain highly resistant to traditional promotional engagement.

Modern platforms like Alpha Sophia increasingly combine:

• CMS Open Payments data,
• claims intelligence,
• ICD-10 trends,
• and provider engagement signals

to help organizations identify these behavioral differences.

For example, two neurologists may treat similar volumes of MS patients. However:

• one physician frequently attends educational dinners and speaker programs,
• while the other rarely engages commercially despite high clinical activity.

Those physicians likely require entirely different engagement strategies.

This becomes especially important in omnichannel orchestration, where organizations increasingly need to determine:

• which channel is most appropriate,
• what type of engagement is likely to resonate,
• and whether a physician should be engaged commercially or scientifically.

Why Many NBA Initiatives Still Struggle

Despite enormous industry investment, many NBA programs still fail to achieve their full potential.

One major reason is fragmented data infrastructure.

Many pharma organizations still operate across disconnected ecosystems involving:

• separate claims vendors,
• siloed CRM systems,
• fragmented engagement platforms,
• and inconsistent provider identifiers.

As a result, commercial recommendations often become incomplete or contradictory.

A physician may appear:

• commercially inactive in CRM systems,
• while simultaneously showing rapidly increasing diagnosis activity in claims data.

Without unified provider intelligence, organizations struggle to generate reliable recommendations.

Another major challenge is explainability.

Commercial teams are understandably skeptical of “black box” recommendations that lack context. If a system recommends prioritizing a physician, field reps need to understand:

• why the recommendation exists,
• what behavioral signals triggered it,
• and what commercial objective the action supports.

The most successful NBA systems increasingly focus not just on prediction accuracy, but on recommendation transparency.

There is also a deeper organizational challenge many companies underestimate:

NBA is not purely an analytics initiative.

It is fundamentally a workflow orchestration problem.

Even highly sophisticated AI systems fail if recommendations are not embedded into:

• CRM workflows,
• field execution,
• omnichannel coordination,
• and commercial operations.

As Deloitte notes in its research on pharma engagement transformation:

“Data and analytics alone do not create customer-centricity. Organizations must redesign engagement models around customer needs.”

That redesign remains extremely difficult for many large pharmaceutical organizations with entrenched commercial structures.

The Future of NBA in Pharma

The future of Next Best Action will likely extend far beyond recommending isolated rep activity.

Increasingly, organizations are moving toward:

• continuous engagement orchestration,
• AI-driven provider intelligence,
• predictive personalization,
• and real-time commercial coordination.

Instead of static physician targeting updates every quarter, organizations are beginning to build:

• continuously evolving provider profiles,
• dynamic engagement pathways,
• and AI-powered commercial workflows that adapt in real time.

In the future, NBA may evolve from:

“what should we do next?”

toward:

“how should the entire engagement journey continuously adapt based on changing provider behavior?”

That shift will become even more important as:

• precision medicine expands,
• healthcare systems continue consolidating,
• and physician engagement becomes increasingly selective.

Ultimately, the pharmaceutical organizations that succeed with NBA will not simply be the ones with the most advanced AI models.

They will be the organizations best able to combine:

• healthcare intelligence,
• workflow orchestration,
• clinical understanding,
• and personalized engagement

into commercial systems that genuinely improve how healthcare providers experience pharmaceutical interaction.